Loading
A phase 3 trial of Disitamab vedotin, Tislelizumab, Capecitabine, Oxaliplatin, Trastuzumab and Pembrolizumab in gastric & gastro-oesophageal junction cancer, run by RemeGen Co., Ltd., now recruiting.
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. is a phase 3 interventional study registered as NCT07315750 by RemeGen Co., Ltd., with 555 participants planned, started 2026-01-01 and due to reach its primary completion in 2029-06-30. Interventions recorded: Disitamab Vedotin, Tislelizumab, CAPOX (oxaliplatin/capecitabine), Trastuzumab and Pembrolizumab.
Shares RemeGen, Oxaliplatin, Trastuzumab, Capecitabine and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Oxaliplatin, Capecitabine and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Monoclonal antibodies, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab, Capecitabine, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Tislelizumab, Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Pembrolizumab and the tag pipeline.